QTREX has filed a prospectus to offer up to 6.8 million ordinary shares for resale by a selling shareholder. The filing outlines the terms for the distribution of existing securities, providing a mechanism for the shareholder to liquidate their holding. The company will not receive any proceeds from this offering, as the shares are being sold by the selling shareholder.

Offering Details

The prospectus details the maximum number of shares to be offered and identifies the selling shareholder as the party offering the securities. The transaction involves the resale of ordinary shares already issued by QTREX.

The filing is available via the SEC's EDGAR database, providing full regulatory disclosure regarding the resale. The prospectus serves as the primary document for potential investors to review the terms of the share offering.

QTREX Quantum Ltd. appointed Dr. Shlomit Chappel-Ram as an independent director effective July 14, 2026, strengthening its Board's technical expertise in Additively Manufactured Electronics (AME). The appointment comes as QTREX advances its AME platform from a validated capability into commercial component production for quantum computing infrastructure. Dr. Chappel-Ram brings direct operating experience in scaling complex hardware, aligning with QTREX's operational phase.

Dr. Chappel-Ram previously served as Vice President of R&D at Nano Dimension Ltd., where she led multidisciplinary teams spanning materials, formulations, chemistry, physics, process engineering, mechanics, software, hardware, and electronics. She co-authored peer-reviewed IEEE research on AME-fabricated, multi-metal-layer antenna architectures. Her background includes directing complex technology programs from early-stage development through regulatory approval and transfer to manufacturing.

Board Strengthening and Strategic Fit

The addition of Dr. Chappel-Ram to the Board is expected to enhance QTREX's ability to commercialize its AME technology. QTREX acquired the AME platform from Nano Dimension Ltd. in April 2026 and is applying it to high-density, thermally optimized quantum connectivity and proprietary, application-specific RF components. Dagi Ben-Noon, Chief Executive Officer of QTREX Quantum, emphasized that her deep technical understanding and proven track record in scaling complex hardware directly match the company's current operational needs.

Professional Background

Dr. Chappel-Ram has served as General Manager of Digma Medical since January 2025, overseeing operations, product development, regulatory and clinical programs, fundraising, and investor communications. From January 2021 to December 2024, she was Digma Medical's Vice President R&D and led Investor Relations activities. Her prior roles include senior R&D positions at Edwards Lifesciences (Cardioband) and Medinol Ltd. She also served as a consultant and advisory board member at Kidron Capital since April 2021 and at NGLi Holdings from March 2023 to March 2024.

Academic Credentials

Dr. Chappel-Ram holds a Ph.D. in Chemistry, summa cum laude, and an MBA from Bar-Ilan University. She completed postdoctoral work in Chemistry and Biochemistry at the City University of New York and finished the Directors and Senior Corporate Officeholders Program at Tel Aviv University’s LAHAV Executive Education.